Company profile
Hemagen Diagnostics, Inc.
OTC: HMGN · Healthcare · Biotechnology
#721 of 1,418 Healthcare companies by revenue27th-percentile growth
EA Score
——FH —DQ —GM —SS 46
v0.1 · 5/100 weight · pillars only
↑ listing tenure, growth stability · ↓ market scale, balance-sheet leverage
Methodology →Revenue TTM
$4.0M
Rev growth YoY (TTM)
-21.4%
Net income (FY)
-$907.3k
Employees
15
as of 2026-08-28
Market cap
$3.1k
as of 2026-08-28
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$4.0M$4.0M2012
Net income-$907.3k-$907.3k2012
Operating income-$437.9k-$437.9k2012
Total assets$2.4M$2.4M2012
Liabilities$6.0M$6.0M2012
Equity-$3.6M-$3.6M2012
Revenue trend
FY2005 – FY2012 · USD
FY05
FY06
FY07
FY08
FY09
FY10
FY11
FY12
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Hemagen Diagnostics, Inc.’s revenue?
Hemagen Diagnostics, Inc. booked $4.0M in FY2012 revenue, contracting 21% year over year — slower than 73% of Healthcare companies we track, at a -22.4% net margin.
Peers · Healthcare
ProPhase Labs, Inc.38DComprehensive Healthcare Systems, Inc.42DInsight Molecular Diagnostics Inc.37DCG Oncology Inc.47DCervoMed Inc.42DTenon Medical, Inc.35DNeighbors
Howard →Key facts
CEOWilliam Hales
SectorHealthcare
IndustryBiotechnology
HeadquartersColumbia, MD
ExchangeOTC: HMGN
Employees15
IPO date1993-02-04
Latest filings
No filings loaded — no CIK (non-SEC filer).
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.